Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/86
Title: Assessment of the 2016 National Institute for Health and Care Excellence high-sensitivity troponin rule-out strategy
Authors: Pickering, J. W.
Cullen, L.
Body, R.
Carlton, E. W.
Kendall, J.
Greenslade, J.
Greaves, K. 
Than, M.
Parsonage, W. A.
Khattab, A.
Issue Date: 2018
Source: 104, (8), 2018, p. 665-672
Pages: 665-672
Journal: Heart
Abstract: OBJECTIVE: We aimed to evaluate the limit of detection of high-sensitivity troponin (hs-cTn) and Thrombolysis In Myocardial Infarction (TIMI) score combination rule-out strategy suggested within the 2016 National Institute for Health and Care Excellence (NICE) Chest Pain of Recent Onset guidelines and establish the optimal TIMI score threshold for clinical use.METHODS: A pooled analysis of adult patients presenting to the emergency department with chest pain and a non-ischaemic ECG, recruited into six prospective studies, from Australia, New Zealand and the UK. We evaluated the sensitivity of TIMI score thresholds from 0 to 2 alongside hs-cTnT or hs-cTnI for the primary outcome of major adverse cardiac events within 30 days.
RESULTS: Data were available for 3159 patients for hs-cTnT and 4532 for hs-cTnI, of these 376 (11.9%) and 445 (9.8%) had major adverse cardiac events, respectively. Using a TIMI score of 0, the sensitivity for the primary outcome was 99.5% (95% CI 98.1% to 99.9%) alongside hs-cTnT and 98.9% (97.4% to 99.6%)%) alongside hs-cTnI, identifying 17.9% and 21.0% of patients as low risk, respectively. For a TIMI score <=1sensitivity was 98.9% (97.3% to 99.7%)%) alongside hs-cTnT and 98.4% (96.8% to 99.4%)%) alongside hs-cTnI, identifying 28.1% and 35.7% as low risk, respectively. For TIMI<=2, meta-sensitivity was <98% with either assay.
CONCLUSIONS: Our findings support the rule-out strategy suggested by NICE. The TIMI score threshold suggested for clinical use is 0. The proportion of patients identified as low risk (18%-21%) and suitable for early discharge using this threshold may be sufficient to encourage change of practice.
TRIAL REGISTRATION NUMBERS: ADAPT observational study/IMPACT intervention trial ACTRN12611001069943.ADAPT-ADP randomised controlled trial ACTRN12610000766011. EDACS-ADP randomised controlled trial ACTRN12613000745741. TRUST observational study ISRCTN no. 21109279.
Carlton, Edward WattsPickering, John William
Greenslade, Jaimi
Cullen, Louise
Than, Martin
Kendall, Jason
Body, Richard
Parsonage, William A
Khattab, Ahmed
Greaves, Kim
Resources: http://scproxy.slq.qld.gov.au/login?url=http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=28864718http://linksource.ebsco.com/athens.b6e6cc08-c492-42af-aec4-c6084e18e68c/linking.aspx?sid=OVID:medline&id=pmid:28864718&id=doi:10.1136%2Fheartjnl-2017-311983&issn=1355-6037&isbn=&volume=104&issue=8&spage=665&date=2018&title=Heart&atitle=Assessment+of+the+2016+National+Institute+for+Health+and+Care+Excellence+high-sensitivity+troponin+rule-out+strategy.&aulast=Carlton&pid=%3CAN%3E28864718%3C%2FAN%3E
Type: Article
Appears in Sites:Sunshine Coast HHS Publications

Show full item record

Page view(s)

170
checked on Mar 13, 2025

Google ScholarTM

Check


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.